84-1195-65　Clara Cell Protein (CC16, CC10, Uteroglobin, Urinary Protein 1, Clara Cell Secretory Protein, Secretoglobin Family 1A Member 1, CCPBP, Clara Cells 10kD Secretory Protein, CC10, UP1, Clara Cell Phospholipid-binding Protein, SCGB1A1, CCSP, UGB) 100ug　C5828-01E

特徴

• Uteroglobin, phospholipid binding, 10kD or 16kD protein (CCSP, CCPBP, CC10 or CC16, respectively) is a small, non-glycosylated secreted protein of the secretoglobin superfamily, (designated 1A, member 1.
• Its name is derived from its very high expression in the pre-implantation uterus.
• It is produced by the non-ciliated, non-mucous secretory cells that predominate in lung bronchioles (Clara cells), and other non-ciliated epithelia that communicate with the external environment.
• Expression is induced by steroid hormones such as estrogen, and enhanced by the non-steroid hormone prolactin.
• Uteroglobin is found in blood, urine and other body fluids.
• Human Uteroglobin cDNA encodes a 21aa signal sequence and a 70aa mature protein.
• It shares 53-56aa identity with mouse, rat, bovine, canine, equine or rabbit Uteroglobin, and is active in mice.
• The mature protein forms a disulfide-linked head-to-tail homodimer of 16kD.
• This homodimer is thought to form a binding pocket that binds hydrophobic ligands such as phospholipids, progesterone and retinols.
• Sequestering of prostaglandins and leukotrienes is anti-inflammatory, while sequestering of carcinogens such as polychlorinated bisphenols is anti-tumorigenic.
• Other immunoregulatory activities of Uteroglobin include cell migration inhibition (by binding the chemotaxis-related formyl peptide receptor FPR2 on dendritic cells), and the inhibition of T cell differentiation to a Th2 phenotype.
• A single nucleotide polymorphism of Uteroglobin, A38G, confers increased risk of asthma.
• Transglutaminase can crosslink Uteroglobin, either to itself or to other proteins such as the adhesion molecule fibronectin.
• Binding of fibronectin to Uteroglobin in the kidney is thought to protect against nephropathy, while binding of the lipocalin-1 receptor has been reported to suppress cancer cell motility and invasion.
• Applications:Suitable for use in ELISA, Immunohistochemistry and Neutralization.
• Other applications not tested.
• Recommended Dilutions:Immunohistochemistry: 5-15ug/ml using Immersion fixed, paraffin-embedded sections in human endometrial cancer tissue
• Neutralization: Measured by its ability to neutralize Uteroglobin­-mediated adhesion of A549 human lung carcinoma cells.
• The Neutralization Dose (ND50) is typically 0.3­-1.2ug/ml in the presence of 5ug/mL recombinant human Uteroglobin
• Optimal dilutions to be determined by the researcher.
• Storage and Stability:Lyophilized and reconstituted products are stable for 12 months after receipt at -20°C.
• Reconstitute with sterile PBS.
• Aliquot to avoid repeated freezing and thawing.
• Store at -20°C.
• For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Further dilutions can be made in assay buffer.